TheStreet Quant Ratings rates Inovio Pharmaceuticals Inc (NYSEMKT:INO) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and poor profit margins. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock opened at $3.40 in last trading session, and closed at $3.72, trading in the range of $3.38 – $3.95. The stock showed a positive weekly performance of 35.27%.
Celladon Corp (NASDAQ:CLDN) announced that the FDA has reviewed and provided clearance for the company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (:RFA) in primary liver cancer, also known as hepatocellular carcinoma. The trial design is based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment. Celsion expects to launch the study in the first half of 2014. Celladon Corp (NASDAQ:CLDN) shares closed at $9.50 on last trade day, by losing – 25.50%. Stock 52 week range is $7.45 – $14.68. Company’s market capitalization is $167.91 million.
Celsion Corporation (NASDAQ:CLSN) announced that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The trial design is based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment. Celsion expects to launch the study in the first half of 2014. Celsion Corporation (NASDAQ:CLSN) stock advanced 3.59% and finished the last session at $3.75. The EPS of the stock remained -2.82. Company’s market capitalization is $51.02 million.
Endocyte, Inc. (NASDAQ:ECYT) Reports Q4 net loss of $0.08 per share vs ($0.15); revs of $17.3 mln vs $15.8 mln CIQ est. Of this revenue, $14.5 million related to the amortization of the upfront license payment, milestones and reimbursable expenditures occurring prior to the fourth quarter of 2013. The remaining $2.8 million of revenue related to amortization of reimbursable expenditures incurred during the fourth quarter of 2013. Guidance Co expects that its cash, cash equivalents and investments will be between $90.0-110.0 mln at Dec. 31, 2014. Endocyte, Inc. (NASDAQ:ECYT) stock opened at $15.43 in last trading session and closed at $15.65. The 52 week range of the stock is $8.18 – $19.00 and the day range was $15.00 – $16.48.